GeNeuro announces successful €17.5 million private placement

Geneva, Switzerland, January 31, 2020 – 08:00 CET – GeNeuro (Euronext Paris: CH0308403085-GNRO), a biopharmaceutical company developing new treatments focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases (the “Company”), today announced the successful completion of a €17.5 million international private placement only to certain qualified and institutional investors of 5,932,201 new ordinary bearer shares of GeNeuro with a par value of CHF 0.05 each (the “New Shares” and the “Offering”, respectively).

The New Shares have been offered at a price of €2.95 each, including nominal value and issue premium (the “Subscription price”).

Bryan, Garnier & Co Limited acted as sole global coordinator and sole bookrunner of the Offering.

“Successfully completing this private placement provides GeNeuro operating capital into mid-2022, and the means to complete the planned study of temelimab in multiple sclerosis (“MS”) patients with disability progression without relapses at the Karolinska Institutet / Academic Specialist Center in Stockholm, and to bring the new amyotrophic lateral sclerosis (“ALS”) antibody to an IND. GeNeuro has also enriched its shareholder base as Institut Mérieux and Eclosion2, who have supported the Company for over a decade, have been joined by other leading international investors.” said Jesús Martin-Garcia, CEO of GeNeuro.

In the Offering, GNEH SAS, a subsidiary of Institut Mérieux and an existing shareholder of GeNeuro (“GNEH”), has subscribed to 2,542,372 New Shares in cash and by way of set-off. As a result, following the Offering GNEH shall own 36.46% of the share capital and 36.65% of the voting rights of the Company on a non-diluted basis and 36.23%, respectively 36.41%, on a fully diluted basis.

GeNeuro intends to use the net proceeds of the Offering to:

- Complete the clinical trial of temelimab in MS to be conducted with the Karolinska Institutet/Academic Specialist Center (ASC), Stockholm, Sweden, with results expected in H2 2021;

- Repay an outstanding €7.5m shareholder loan granted by GNEH to GeNeuro on December 20, 2018, whereby GNEH shall partly fund such repayment through the purchase price owed for its New Shares (€0.1 million in cash and €7.4 million by way of set-off);

- Advance the preclinical program of GNK301, an anti-HERV-K monoclonal antibody being developed for ALS, up to IND submission to the FDA, expected in H1 2021; and

- Cover the Company’s other pre-clinical programs and operating expenses, extending its financial visibility to mid-2022.

The New Shares issued will represent 40.5% of the Company’s share capital prior to the Offering on a non-diluted basis and 28.8% of the Company’s share capital after the Offering.
In accordance with Article 5bis of the Company’s Articles of Association, as amended by its General Shareholders’ meeting of May 24, 2018, the Board of Directors of the Company approved on January 30, 2020 the issuance of the New Shares and the Subscription Price and waived the preferential subscription rights (the “Capital increase”).

The Subscription Price represents a discount of 7% on the closing market price of the Company’s shares on Euronext Paris on the last trading day preceding the closing date of the Offering, i.e. €3.18 on January 30, 2020.

Following the registration of the Capital Increase by the Commercial registry of Geneva expected to occur on January 31, 2020, the Company’s share capital will be composed of 20,590,319 ordinary bearer shares with a nominal value of CHF 0.05 each.

Based on the information available to the Company, the breakdown of the Company’s share capital and voting rights before and after the Capital Increase is as follows:

<table>
<thead>
<tr>
<th>Ownership and voting rights before the Capital Increase</th>
<th>Ownership and voting rights after the Capital Increase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of shares and voting rights</td>
<td>% of share capital and voting rights</td>
</tr>
<tr>
<td>Eclosion2 &amp; Cie SCPC</td>
<td>6,367,608</td>
</tr>
<tr>
<td>GNEH SAS (1)</td>
<td>4,965,654</td>
</tr>
<tr>
<td>Servier International BV</td>
<td>1,254,596</td>
</tr>
<tr>
<td>Sub-total</td>
<td>12,587,858</td>
</tr>
<tr>
<td>Total employees and directors</td>
<td>147,437</td>
</tr>
<tr>
<td>Treasury shares (2)</td>
<td>105,881</td>
</tr>
<tr>
<td>Free Float</td>
<td>1,816,942</td>
</tr>
<tr>
<td>TOTAL</td>
<td>14,658,118</td>
</tr>
</tbody>
</table>

(1) Institut Mérieux and bioMérieux SA reported to the AMF on November 9, 2018, that they have contributed their shareholdings in GeNeuro to GNEH SAS (a holding company held 81.1% by Institut Mérieux and 18.9% by bioMérieux).

(2) Shares held in treasury have their voting rights suspended in accordance with Swiss law.

The settlement and delivery and admission to trading date of the New Shares to be issued upon registration of the Capital Increase by the Commercial registry of Geneva (expected on January 31, 2020), is scheduled for February 4, 2020. The New Shares will carry immediate dividend and voting rights and will be listed on the regulated market of Euronext Paris market under ISIN CH0308403085—GNRO.

In connection with the Offering, GeNeuro has undertaken, subject to standard exceptions, not to issue equity securities or securities giving rise to equity securities for a 90-day period and GNEH SAS, Eclosion2 & Cie SCPC, Servier, and the directors, officers and key employees who hold shares or stock options of the Company have agreed to a 90-day lockup period, subject to standard exceptions.

Detailed information about the Company, specifically its activity, its earnings, and the corresponding risk factors, appears in the Company’s 2018 Registration Document registered with the AMF on April 29, 2019 under number R.19-017. As a result of admission to trading of the New Shares on Euronext Paris, which shall represent more than 20% of the existing shares of the Company, the Company is required to prepare and submit a prospectus for approval by the AMF. The Company intends to file with the AMF on January 31 2020 a Universal Registration Document which, together with a securities note, and a summary (included in the securities note), will form a prospectus. This prospectus will, upon its approval by the AMF, provide the most recent information available on the Company. The 2018 Registration Document, and when approved, the Universal Registration Document may be consulted, along with the Company’s other regulated information and all its press releases, on its website (www.geneuro.com).
About GeNeuro

GeNeuro’s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA. GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has 23 employees and rights to 17 patent families protecting its technology.

For more information, visit: https://www.geneuro.com

Contacts

<table>
<thead>
<tr>
<th>GeNeuro</th>
<th>NewCap (France)</th>
<th>Halsin Partners</th>
<th>LifeSci Advisors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jesús Martin-Garcia, Chairman and CEO</td>
<td>Investor Relations – Mathilde Bohin / Louis-Victor Delouvrier +33 1 44 71 98 52 Media Relations – Arthur Rouillé</td>
<td>Media Relations – Mike Sinclair</td>
<td>Investor Relations – Chris Maggos</td>
</tr>
<tr>
<td></td>
<td>+41 22 552 48 00</td>
<td>+33 1 44 71 94 98</td>
<td>+44 20 7318 2955</td>
</tr>
<tr>
<td><a href="mailto:investors@geneuro.com">investors@geneuro.com</a></td>
<td><a href="mailto:geneuro@newcap.eu">geneuro@newcap.eu</a></td>
<td><a href="mailto:msinclair@halsin.com">msinclair@halsin.com</a></td>
<td><a href="mailto:chris@lifesciadvisors.com">chris@lifesciadvisors.com</a></td>
</tr>
</tbody>
</table>

Legal notice

This announcement and the information contained herein do not constitute either an offer to sell or purchase, or the solicitation of an offer to sell or purchase, securities of GeNeuro S.A. (the “Company”).

No communication or information in respect of the offering by the Company of its shares may be distributed to the public in any jurisdiction where registration or approval is required. No steps have been taken or will be taken in any jurisdiction where such steps would be required. The offering or subscription of shares may be subject to specific legal or regulatory restrictions in certain jurisdictions. The Company takes no responsibility for any violation of any such restrictions by any person.

This announcement does not, and shall not, in any circumstances, constitute a public offering nor an invitation to the public in connection with any offer. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.

This announcement is an advertisement and not a prospectus within the meaning of Regulation (EU) 2017/1129 (the “Prospectus Regulation”), as implemented in each member State of the European Economic Area.

A listing prospectus comprised of a Universal Registration Document and a Securities Note (including a summary of the prospectus) will be submitted by the Company to the approval of the AMF in relation to the admission to trading of the New Shares issued. Once approved by the AMF, the prospectus will be available on the Company’s website (www.geneuro.com) and on the AMF website (www.amf-france.org).

No action has been undertaken or will be undertaken to make available any shares of the Company to any retail investor in the European Economic Area. For the purposes of this press release, the expression “retail investor” means a person who is one (or more) of the following:

- a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, "MiFID II"); or
- a customer within the meaning of Directive 2016/97/EU, as amended, where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or not a “qualified investor” as defined in the Prospectus Regulation; and
- the expression “offer” includes the communication in any form and by any means of sufficient information on the terms of the offer and the shares to be offered so as to enable an investor to decide to purchase or subscribe the shares.

The Company’s shares in connection with the Capital Increase are not being offered or sold, directly or indirectly, to the public in France to persons other than qualified investors. Any offer or transfer of shares of the Company or distribution of offer documents has only been and will only be made in France to qualified investors as defined by Article 2(e) of the Prospectus Regulation and in accordance with Articles L. 411-1 and L. 411-2 of the French Monetary and Financial Code.

This document may not be distributed, directly or indirectly, in or into the United States. This document does not constitute an offer of securities for sale nor the solicitation of an offer to purchase securities in the United States or in any other jurisdiction.
any other jurisdiction where such offer may be restricted. Securities may not be offered or sold in the United States absent registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements thereof. The securities of the Company have not been and will not be registered under the Securities Act, and the Company does not intend to make a public offering of its securities in the United States. Copies of this document are not being, and should not be, distributed in or sent into the United States.

The distribution of this document (which term shall include any form of communication) is restricted pursuant to Section 21 (Restrictions on financial promotion) of Financial Services and Markets Act 2000 (“FMSA”). This document is only being distributed to and directed at persons who (i) are outside the United Kingdom, (ii) have professional experience in matters relating to investments and who fall within the definition of investment professionals in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion Order 2005 (as amended) (the “Financial Promotion Order”), (iii) are persons falling within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Promotion Order or (iv) are persons to whom this communication may otherwise lawfully be communicated (all such persons referred to in (i), (ii), (iii) and (iv) above together being referred to as “Relevant Persons”). This document must not be acted on or relied on in the United Kingdom by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons, and will be engaged in only with such persons in the United Kingdom.

This document may not be distributed, directly or indirectly, in or into the United States, Canada, Australia, Japan South Africa or any other jurisdiction in which it would be unlawful to do so.

Disclaimer

This press release contains certain forward-looking statements and estimates concerning GeNeuro’s financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words, such as “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “plan,” “potential,” “predict,” “objective,” “should,” or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management’s current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the company’s control. Consequently, the actual results, financial condition, performances and/or achievements of GeNeuro or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and GeNeuro undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law.